Monday, 2 June 2025
  
Login

Australia's most trusted
source of pharma news

Monday, 02 June 2025
News

AZ's next oncology move revealed

Posted 27 May 2025 AM

Just days after approving AstraZeneca’s Datroway, the TGA has hinted that the company’s next breast cancer treatment could arrive by early next year.

An update to the regulator’s prescription medicine determinations and designations list shows that camizestrant was granted the priority review pathway on 5 May for use in combination with a CDK4/6 inhibitor for adults with HR-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during first line endocrine-based therapy.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (15)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (4)

Devices (1)

Other (21)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.